Pure Biologics S.A. Logo

Pure Biologics S.A.

PUR | WAR

Overview

Corporate Details

ISIN(s):
PLPRBLG00010 (+1 more)
LEI:
2594002TXS19AUYHIF82
Country:
Poland
Address:
WROCŁAW LEGNICKA 48E, 54-202 WROCŁAW
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Pure Biologics S.A. is a biopharmaceutical company specializing in the discovery and development of innovative biological drugs and non-systemic therapies. The company's core focus is on creating novel, non-biosimilar therapeutic molecules, primarily utilizing antibody and aptamer technologies. Its therapeutic portfolio targets significant unmet medical needs, with a primary emphasis on immuno-oncology and autoimmunity. Pure Biologics also engages in the research and development of diagnostic tests and medical devices for therapeutic applications. The company aims to develop molecules that activate the immune system to combat cancer and other diseases, positioning itself as a key player in the development of next-generation biological treatments.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Pure Biologics S.A.. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-07-18 15:21
Share Issue/Capital Change
Zawarcie umowy inwestycyjnej z ACRX Investments Limited - Content (PL)
Polish 3.3 KB
2025-07-10 22:52
Regulatory News Service
Rejestracja akcji na okaziciela serii N w depozycie papierów wartościowych prow…
Polish 1.1 KB
2025-07-09 18:52
Share Issue/Capital Change
Podjęcie przez Zarząd Spółki uchwały w sprawie ustalenia ceny emisyjnej oraz ha…
Polish 1.1 KB
2025-07-08 18:35
Share Issue/Capital Change
Treść uchwały nr 17 ZWZ z dnia 30 czerwca 2025 r.
Polish 156.3 KB
2025-07-08 18:35
Post-Annual General Meeting Information
Korekta raportu bieżącego nr 23/2025 w sprawie treści uchwał podjętych przez Zw…
Polish 1.7 KB
2025-06-30 18:05
Declaration of Voting Results & Voting Rights Announcements
Lista Akcjonariuszy posiadających co najmniej 5% głosów na Zwyczajnym Walnym Zg…
Polish 1.5 KB
2025-06-30 17:38
Post-Annual General Meeting Information
Treść uchwał podjętych przez ZWZ Spółki w dniu 30 czerwca 2025 r.
Polish 352.3 KB
2025-06-30 17:38
Post-Annual General Meeting Information
Treść uchwał podjętych przez Zwyczajne Walne Zgromadzenie Pure Biologics S.A. 3…
Polish 766 bytes
2025-06-30 10:04
Capital/Financing Update
Rozpoczęcie negocjacji z ACRX Investments - Content (PL)
Polish 1.3 KB
2025-06-26 19:07
Legal Proceedings Report
Złożenie przez Zarząd wniosku o ogłoszenie upadłości Spółki - Content (PL)
Polish 1.8 KB
2025-06-23 15:13
Regulatory News Service
Sprzedaż spółki DOTO MEDICAL sp. z o.o. oraz platformy aptamerowej - Content (P…
Polish 1.3 KB
2025-06-05 19:43
Legal Proceedings Report
Potwierdzenie rozwiązania umów o dofinansowanie - Content (PL)
Polish 1.8 KB
2025-06-03 20:25
Board/Management Information
Sprawozdanie Rady Nadzorczej Spółki za rok 2024
Polish 643.7 KB
2025-06-03 20:25
Post-Annual General Meeting Information
Projekty uchwał ZWZ Spółki zwołanego na dzień 30.06.2025
Polish 328.0 KB
2025-06-03 20:25
Pre-Annual General Meeting Information
Treść ogłoszenia o zwołaniu ZWZ Spółki na dzień 30.06.2025
Polish 198.8 KB

Automate Your Workflow. Get a real-time feed of all Pure Biologics S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Pure Biologics S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Purple Biotech Ltd. Logo
Develops first-in-class cancer therapies targeting tumor immune evasion and drug resistance.
Israel PPBT
Develops uncopiable atomic fingerprints for anti-counterfeiting, verifiable by smartphone.
United Kingdom N/A
QUANTUM BLOCKCHAIN TECHNOLOGIES PLC Logo
R&D firm using AI and quantum computing to create efficient technologies for Bitcoin mining.
United Kingdom QBT
Quantum Genomics Logo
Develops digital twin solutions to simulate drug effects and personalize treatments.
France ALQGC
QUIA PHARMA AB Logo
Develops enhanced drugs using a patented, releasable pegylation drug delivery platform.
Sweden QUIA
Read Gene Spolka Akcyjna Logo
Develops DNA tests to identify genetic cancer risk for early detection and prevention.
Poland RDG
RELIEF Therapeutics Holding AG Logo
Developing and commercializing novel therapies for rare and ultra-rare diseases.
Switzerland RLF
Respiratorius AB Logo
Developing innovative drug candidates to enhance standard therapies for aggressive cancers.
Sweden RESP
ROQUEFORT THERAPEUTICS PLC Logo
Developing novel immuno-oncology medicines for hard-to-treat, resistant cancers.
United Kingdom ROQ
United States of America N/A